



Research Study Opportunity for Individuals with Rhabdomyosarcoma

Researchers at the National Cancer Institute are looking for volunteers with alveolar or embryonal rhabdomyosarcoma to participate in a clinical trial testing the effectiveness of an investigational combination of antitumor drugs. Participants will receive ganitumab plus dasatinib, two drugs that may help to slow tumor progression.

All participants will take a daily pill of dasatinib at home and visit the NIH Clinical Center in Bethesda, MD, every 2 weeks for an infusion of ganitumab. A participant can continue to receive treatment for as long as it remains effective and they are healthy enough to attend their visits.

This study involves

- An initial screening at NIH with lab work and imaging scans (e.g., CT Scan)
- An optional pre-treatment tumor biopsy
- Daily pill of dasatinib (taken at home)
- Biweekly outpatient visits to NIH for a ganitumab infusion
- Follow up with your home doctor for 30 days after you stop treatment

You may be eligible if you

- Have been diagnosed with refractory alveolar or embryonal rhabdomyosarcoma that returned or did not respond to treatment
- Are able to swallow pills
- Are not pregnant or breastfeeding
- Do not have type 1 diabetes
- Have not had radiation pneumonitis
- Do not have brain metastases



For more information or to enroll, contact the NIH Clinical Center Office of Patient Recruitment and mention study #17-C-0049.



Toll Free: 800-411-1222
TTY/ASCII: 800-877-8339



PRPL@cc.nih.gov



<https://go.usa.gov/xA38K>



NIH...Turning Discovery into Health®